Baker Tilly Wealth Management LLC Sells 105 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Baker Tilly Wealth Management LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,600 shares of the medical research company’s stock after selling 105 shares during the period. Baker Tilly Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $990,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of TMO. BDF Gestion bought a new stake in Thermo Fisher Scientific during the second quarter valued at $6,368,000. Lord Abbett & CO. LLC raised its holdings in shares of Thermo Fisher Scientific by 1.9% in the 1st quarter. Lord Abbett & CO. LLC now owns 78,247 shares of the medical research company’s stock valued at $45,478,000 after acquiring an additional 1,480 shares in the last quarter. Advisors Capital Management LLC grew its holdings in shares of Thermo Fisher Scientific by 5.8% during the first quarter. Advisors Capital Management LLC now owns 111,169 shares of the medical research company’s stock worth $64,613,000 after purchasing an additional 6,089 shares in the last quarter. MV Capital Management Inc. raised its stake in Thermo Fisher Scientific by 13.1% in the first quarter. MV Capital Management Inc. now owns 199 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 23 shares in the last quarter. Finally, American National Bank & Trust Co. VA bought a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $7,306,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TMO. Stephens assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective on the stock. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Evercore ISI cut their target price on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday. Finally, Sanford C. Bernstein lowered their price target on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a “market perform” rating for the company in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $649.33.

Thermo Fisher Scientific Stock Down 0.5 %

TMO stock opened at $554.38 on Monday. The company has a market capitalization of $211.77 billion, a price-to-earnings ratio of 34.76, a price-to-earnings-growth ratio of 3.66 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The business’s 50 day moving average price is $605.12 and its two-hundred day moving average price is $584.07. Thermo Fisher Scientific Inc. has a fifty-two week low of $420.21 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The firm had revenue of $10.60 billion for the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.69 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.